Maike Janssen
A5018380807- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- COVID-19 Impact on Reproduction
- Hematopoietic Stem Cell Transplantation
- Single-cell and spatial transcriptomics
- Platelet Disorders and Treatments
- Immune cells in cancer
- Reproductive System and Pregnancy
- Histone Deacetylase Inhibitors Research
- Pregnancy and Medication Impact
- Endometriosis Research and Treatment
- Immune Cell Function and Interaction
- Epigenetics and DNA Methylation
- COVID-19 and healthcare impacts
- Gout, Hyperuricemia, Uric Acid
- Adrenal Hormones and Disorders
- Cancer Genomics and Diagnostics
University Hospital Heidelberg
2019-2025
Heidelberg University
2019-2025
European Molecular Biology Laboratory
2022-2023
University Medical Center Hamburg-Eppendorf
2016-2019
Universität Hamburg
2016-2019
Saarland University
2011
Inter-patient variability and the similarity of healthy leukemic stem cells (LSCs) have impeded characterization LSCs in acute myeloid leukemia (AML) their differentiation landscape. Here, we introduce CloneTracer, a novel method that adds clonal resolution to single-cell RNA-seq datasets. Applied samples from 19 AML patients, CloneTracer revealed routes differentiation. Although residual preleukemic dominated dormant cell compartment, active resembled counterpart retained erythroid...
The BCL2 inhibitor venetoclax (VEN) in combination with azacitidine (5-AZA) is currently transforming acute myeloid leukemia (AML) therapy. However, there a lack of clinically relevant biomarkers that predict response to 5-AZA/VEN. Here, we integrated transcriptomic, proteomic, functional, and clinical data identify predictors 5-AZA/VEN response. Although cultured monocytic AML cells displayed upfront resistance, differentiation was not predictive our patient cohort. We identified leukemic...
Abstract Patients with cancer are at high risk of severe coronavirus disease 2019 (COVID-19), morbidity and mortality. Furthermore, impaired humoral response renders acute respiratory syndrome 2 (SARS-CoV-2) vaccines less effective treatment options scarce. Randomized trials using convalescent plasma missing for high-risk patients. Here, we performed a randomized, open-label, multicenter trial ( https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001632-10/DE ) in hospitalized...
Immunotherapies, such as chimeric antigen receptor (CAR) modified T cells and antibody-drug conjugates (ADCs), have revolutionized the treatment of cancer, especially lymphoid malignancies. The application targeted immunotherapy to patients with acute myeloid leukemia (AML) has been limited in particular by lack a tumor-specific target antigen. Gemtuzumab ozogamicin (GO), an ADC targeting CD33, is only approved immunotherapeutic agent AML. In our study, we introduce CD33-directed...
Clonal hematopoiesis (CH) is an age-related condition driven by stem and progenitor cells harboring recurrent mutations linked to myeloid neoplasms. Currently, potential effects on hematopoiesis, cell function regenerative under stress conditions are unknown. We performed targeted DNA sequencing of 457 hematopoietic grafts collected for autologous transplantation (ASCT) in myeloma patients correlated our findings with high-dimensional longitudinal clinical laboratory data (26,510 points...
Abstract Venetoclax/azacitidine combination therapy is effective in acute myeloid leukemia (AML) and tolerable for older, multimorbid patients. Despite promising response rates, many patients do not achieve sustained remission or are upfront refractory. Identification of resistance mechanisms additional therapeutic targets represent unmet clinical needs. By using a genome-wide CRISPR/Cas9 library screen targeting 18,053 protein- coding genes human AML cell line, various conferring to...
Immunocompromised patients are at high risk to fail clearance of SARS-CoV-2. Prolonged COVID-19 constitutes a health and management problem as cancer treatments often have be disrupted. As SARS-CoV-2 evolves, new variants concern emerged that evade available monoclonal antibodies. Moreover, antiviral therapy promotes escape mutations, particularly in immunocompromised patients. These frequently suffer from prolonged infection. No successful treatment has been established for persistent Here,...
<p>Bcl-2 family gene expression in LSCs predicts vitro response to HMA/VEN</p>
<p>Subpopulation specific Bcl-2 family levels and time on HMA/Venetoclax</p>
<p>Transcriptomic and functional characterization of LSC-like cells</p>
<p>Cell line sensitivity and additional patient data</p>
<p>Subpopulation specific Bcl-2 family levels and response to HMA/Venetoclax</p>
<p>Comparison of MAC-Score and BH-3 profiling based response prediction</p>
<p>MAC-Score predict response within mutational subgroups</p>
<p>MAC-Score predict response within mutational subgroups</p>
<p>Cell line sensitivity and additional patient data</p>
<p>Subpopulation specific Bcl-2 family levels and time on HMA/Venetoclax</p>
<p>Transcriptomic and functional characterization of LSC-like cells</p>
<p>Bcl-2 family gene expression in LSCs predicts vitro response to HMA/VEN</p>